Journal
CELLULAR SIGNALLING
Volume 87, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cellsig.2021.110106
Keywords
DNA damage response signalling; Homologous recombination DNA repair; Mps one binder 2 (MOB2); Personalised PARP inhibitor treatments
Categories
Funding
- BBSRC [BB/I021248/1]
- Wellcome Trust [090090/Z/09/Z]
- TUBITAK [119S007]
- CRUK City of London Centre [C7893/A26233]
Ask authors/readers for more resources
The study reveals that hMOB2 regulates double-strand break repair by homologous recombination, impacting the response of cancer cells to treatment. Loss of hMOB2 increases vulnerability of cancer cells to PARP inhibitors.
Monopolar spindle-one binder (MOBs) proteins are evolutionarily conserved and contribute to various cellular signalling pathways. Recently, we reported that hMOB2 functions in preventing the accumulation of endogenous DNA damage and a subsequent p53/p21-dependent G1/S cell cycle arrest in untransformed cells. However, the question of how hMOB2 protects cells from endogenous DNA damage accumulation remained enigmatic. Here, we uncover hMOB2 as a regulator of double-strand break (DSB) repair by homologous recombination (HR). hMOB2 supports the phosphorylation and accumulation of the RAD51 recombinase on resected single-strand DNA (ssDNA) overhangs. Physiologically, hMOB2 expression supports cancer cell survival in response to DSBinducing anti-cancer compounds. Specifically, loss of hMOB2 renders ovarian and other cancer cells more vulnerable to FDA-approved PARP inhibitors. Reduced MOB2 expression correlates with increased overall survival in patients suffering from ovarian carcinoma. Taken together, our findings suggest that hMOB2 expression may serve as a candidate stratification biomarker of patients for HR-deficiency targeted cancer therapies, such as PARP inhibitor treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available